Background-Patients with heart failure and coronary artery disease often undergo coronary artery bypass grafting, but assessment of the risk of an adverse outcome in these patients is difficult. To evaluate the ability of biomarkers to contribute independent prognostic information in these patients, we measured levels in patients enrolled in the biomarker substudies of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. Patients in STICH Hypothesis 1 were randomized to medical therapy or coronary artery bypass grafting, whereas those in STICH Hypothesis 2 were randomized to coronary artery bypass grafting or coronary artery bypass grafting with left ventricular reconstruction. Methods and Results-In substudy patients assigned to STICH Hypothesis 1 (n=606), plasma levels of soluble tumor necrosis factor-α receptor-1 (sTNFR-1) and brain natriuretic peptide (BNP) were highly predictive of the primary outcome variable of mortality by univariate analysis (BNP: χ 2 =40.6; P<0.0001 and sTNFR-1: χ 2 =38.9; P<0.0001). When considered in the context of multivariable analysis, both BNP and sTNFR-1 contributed independent prognostic information beyond the information provided by a large array of clinical factors independent of treatment assignment. Consistent results were seen when assessing the predictive value of BNP and sTNFR-1 in patients assigned to STICH Hypothesis 2 (n=626). Both plasma levels of BNP (χ 2 =30.3) and sTNFR-1 (χ 2 =45.5) were highly predictive in univariate analysis (P<0.0001) and in multivariable analysis for the primary end point of death or cardiac hospitalization. In multivariable analysis, the prognostic information contributed by BNP (χ 2 =6.0; P=0.049) and sTNFR-1 (χ 2 =8.8; P=0.003) remained statistically significant even after accounting for other clinical information. Although the biomarkers added little discriminatory improvement to the clinical factors (increase in c-index ≤0.1), net reclassification improvement for the primary end points was 0.29 for BNP and 0.21 for sTNFR-1 in the Hypothesis 1 cohort, and 0.15 for BNP and 0.30 for sTNFR-1 in the Hypothesis 2 cohort, reflecting important predictive improvement. Conclusions-Elevated levels of sTNFR-1 and BNP are strongly associated with outcomes, independent of therapy, in 2 large and independent studies, thus providing important cross-validation for the prognostic importance of these 2 biomarkers. (Circ Heart Fail. 2013;6:461-472.)
H eart failure secondary to systolic dysfunction affects >5 million individuals in the United States. In the majority of these patients, their left ventricular dysfunction is attributable to coronary artery disease. 1 Patients with heart failure and symptomatic coronary artery disease often undergo coronary artery bypass grafting (CABG) as do some patients with asymptomatic coronary disease; however, surgical intervention in patients with symptomatic disease is often associated with a high morbidity and mortality. A group of clinical indexes were developed to help assess the risk for an adverse outcome in patients undergoing CABG. [2] [3] [4] [5] [6] However, when Orr et al 7 assessed the validity of 4 severity-adjusted models that used clinical metrics to predict mortality after CABG, they found that the predicted mortality rate varied by a factor of 3.3 from the lowest to highest leading the investigators to suggest that the use of these models for individual patient risk estimates is risky because of the significant discrepancies in individual predictions created by each model. More recently, biomarkers have been shown to predict long-term morbidity and mortality in patients with heart failure secondary to diminished left ventricular function [8] [9] [10] ; however, the association of biomarkers with outcomes in patients with heart failure who are undergoing CABG has not been defined.
Clinical Perspective on p 472
The Surgical Treatment for Ischemic Heart Failure (STICH) trials provided the opportunity to test the hypothesis that biomarkers are predictive of risk in patients with heart failure undergoing CABG. The STICH trial was designed to address 2 areas of equipoise. 11 First, STICH Hypothesis 1 evaluated whether patients with coronary artery disease and left ventricular dysfunction benefit from the combination of optimal medical therapy and CABG when compared with optimal medical therapy alone. In STICH Hypothesis 2, we tested whether patients with left ventricular dysfunction who were undergoing CABG benefited from the addition of left ventricular reconstruction. For patients assigned to Hypothesis 1, the difference between medical therapy alone and medical therapy plus CABG with respect to the primary end point of death from any cause was not statistically significant. 12 For patients assigned to STICH Hypothesis 2, the addition of surgical ventricular reconstruction to CABG did not reduce the primary outcome variable of death or hospitalization for a cardiac cause. 13 To test the hypothesis that plasma levels of biomarkers were associated with outcome in patients with ischemic heart failure being considered for surgical revascularization, we measured levels of norepinephrine, brain natriuretic peptide (BNP), and the soluble tumor necrosis factor-α receptor-1 (sTNFR-1) in patients enrolled in the 2 STICH studies who participated in the STICH biomarker substudy. These 3 biomarkers were chosen because each had been shown to be associated with outcomes in patients with heart failure. [8] [9] [10] STICH Hypothesis 1 and STICH Hypothesis 2 provided 2 discrete investigational groups in which to test and confirm the hypothesis that biomarkers are predictive of clinically important outcomes in ischemic heart failure patients eligible for cardiac surgery.
Methods

Study Design
The rationale and design of the STICH trial were presented previously in detail. [11] [12] [13] In brief, STICH enrolled 2136 patients with a left ventricular ejection fraction ≤35% and coronary artery disease that was amenable to CABG. All patients underwent cardiac imaging for assessment of left ventricular function and wall motion with cardiac MRI, radionuclide, or echocardiography, and predefined baseline variables were recorded. 12 Patients were then assigned by the enrolling physician to 1 of 3 strata. Stratum A included patients who were eligible for either medical therapy alone or medical therapy plus CABG. Stratum B included patients who were eligible for medical therapy alone, medical therapy plus CABG, or medical therapy plus CABG and surgical left-ventricular reconstruction (SVR). Stratum C patients were eligible for medical therapy plus CABG or medical therapy plus CABG and left ventricular reconstruction. Patients were then randomly assigned in equal proportions to 1 of the treatment options for which they were eligible. All of the patients in stratum A and some of the patients in stratum B were randomly assigned to medical therapy or medical therapy plus CABG (STICH Hypothesis 1). All of the patients in stratum C and some of the patients in stratum B were randomly assigned to medical therapy and CABG or to medical therapy plus CABG and SVR (STICH Hypothesis 2). The 76 patients randomized to CABG in stratum B fit the criteria for assignment to either Hypothesis 1 or 2. Those patients and their biomarker data were analyzed with the Hypothesis 1 cohort. All patients received pharmacological or device therapy based on consensus guideline recommendations. 14 The Biomarker substudy was approved by the institutional review board of Thomas Jefferson University; however, approval from the institutional review board was also obtained from each institution participating in the Biomarker substudy of the STICH trial and all patients provided written informed consent.
In STICH Hypothesis 2, hospitalizations were adjudicated and classified by an independent Clinical Events Committee because cardiovascular hospitalization was a component of the primary end point. In STICH Hypothesis 1, there was an identical adjudication process for reviewing and classifying hospitalizations, which continued until the completion of STICH Hypothesis 2, at which point (because of limited resources), hospitalizations were no longer adjudicated by the independent committee because that information was not part of the primary Hypothesis 1 end point. Thereafter, cause of hospitalization was site reported.
Sample Collection
Blood samples for measurement of plasma biomarkers were drawn at baseline after inserting a 20-or 21-gauge butterfly needle into an arm vein and placing the subject in a quiet room in a supine position for 30 minutes. The first 3 mL of blood was discarded and a sample was then placed in an EDTA containing tube for measurement of norepinephrine. Blood samples for measurement of sTNFR-1 and BNP were then collected in endotoxin-free EDTA tubes to minimize ex vivo production and catabolism of cytokines. No other biomarkers were measured. All samples were immediately stored on ice, centrifuged within 30 minutes, and the plasma was separated and rapidly frozen at −70°C. Samples were shipped in batches on dry ice from individual centers to the biomarker core laboratory. Samples were logged in using bar codes and stored at −80°C until they were forwarded on dry ice to laboratories for analysis of norepinephrine (M.R. Bristow 
Measurement of Biomarker Levels
Norepinephrine was assayed from −80°C stored plasma by HPLCelectrochemical detection, using an Agilent 1100 HPLC system (Palo Alto, CA), ESA Plasma Catecholamine Analysis Kits (Chelmsford, MA), and a Coulochem III Multi-Electrode Electrochemical Detector (ESA, [Chelmsford, MA]) according to the manufacturers' specifications.
BNP assays were initially performed at the BNP core facility at the Veterans Administration Hospital, San Diego, using the Bayer ADVIACentaur BNP assay. 15 During the 10-year course of the STICH trial, the BNP core laboratory was moved from San Diego to the clinical chemistry laboratory at Thomas Jefferson University Hospital. There, BNP levels were measured using a similar 2-site sandwich immunoassay with a chemiluminescent indicator, but we used the Biosite Triage BNP reagents and the Beckam Coulter Unicel DxI platform. The normal range of BNP value for the laboratory was <125 pg/mL. There was a high degree of correlation (r=0.964) between the 2 methodologies, which allowed us to include all available BNP measurements using a simple regression adjustment to standardize the measurements from 1 core laboratory to be comparable with the measurements from the other core laboratory. The Thomas Jefferson measurements were used as the standard for these analyses.
Plasma levels of sTNFR-1 were measured using an ELISA assay (RIO Systems, Minneapolis, MN) as previously described. 16 To safeguard against the presence of heterophile antibodies, all cytokine assays were performed using ≥1 serial dilution to ensure that the samples diluted appropriately; subsequent dilutions were performed as necessary. The normal value is a mean of 1198 pg/mL. In preliminary control experiments, we determined that the process of storing and shipping the plasma samples to the Core Laboratory resulted in negligible change in the detectable levels of norepinephrine, BNP, or sTNFR-1.
Statistical Analysis
Data were descriptively summarized using the median and interquartile range for continuous variables and frequencies and percentages for categorical variables.
A unique feature of STICH is that it consisted of 2 different studies (Hypothesis 1 and Hypothesis 2), thus enabling an examination and confirmation of the relationships of the biomarkers with clinical outcomes in 2 separate studies. Although we sought to acquire samples for biomarker analysis in every patient, because of the international scope of the STICH program, there were restrictions in some participating countries or centers where the collection/shipping of samples was not possible. Because samples could not be obtained in every randomized patient, we examined the baseline characteristics and outcomes of patients for whom biomarker data were available compared with the patients without samples to assess the degree to which the biomarker substudy cohort was representative of the overall study population. The distributions of continuous variables were compared between these groups using the Wilcoxon rank-sum test, and categorical variables were compared using conventional χ 2 statistics. The primary end point in each trial (mortality in Hypothesis 1 and death or cardiovascular hospitalization in Hypothesis 2) was also compared between patients in the biomarker substudy compared with patients who were not included. Event rate estimates in each group and for each end point were calculated using the Kaplan-Meier method 17 and statistically compared using the Cox proportional hazards regression model. 18 Finally, the randomized treatment comparison for the primary end point in each trial was examined among patients in the biomarker substudy compared with the excluded patients to assess comparability of treatment comparisons in the biomarker substudy cohort compared with the overall trial primary results.
Treating the biomarker measurements as continuous variables, the nature (shape) and strength of the relationships of each biomarker with the clinical outcomes of (1) death and (2) death or cardiac hospitalization were examined by modeling the relationship using restricted cubic spline functions within the framework of the Cox regression model. 19 Where the relationships were nonlinear, a parsimonious model using piecewise linear splines was used to characterize the relationship. 19 These relationships were assessed separately in the Hypothesis 1 and Hypothesis 2 cohorts to examine the consistency of the relationships across the 2 studies.
Once the nature of the relationship was established for each biomarker, we then examined the extent to which the biomarkers contributed independent prognostic information for death and for death or cardiac hospitalization. Using multivariable analyses with the Cox regression model and summarizing the results in terms of likelihood ratio χ 2 statistics and corresponding P values, as well as hazard ratios (HRs) and confidence intervals (CIs), we assessed whether any of the biomarkers (norepinephrine, BNP, or sTNFR-1) contributed significant independent prognostic information to the array of other baseline clinical variables available in these patients. The other clinical variables included age, sex, race, New York Heart Association heart failure classification, history of (1) myocardial infarction, (2) stroke, (3) diabetes mellitus, (4) atrial fibrillation, and (5) hyperlipidemia, creatinine, hemoglobin, coronary anatomy characterized by the Duke Coronary Artery Disease index, end-systolic volume index, mitral regurgitation, whether the patient could perform a 6-minute walk test, randomization stratum, and randomized treatment assignment. In addition to the Cox regression assessments described above, we also used the c-index for time-to-event data 20 (analogous to the area under the receiver operating characteristic curve in the case of a binary end point) and calculated the extent to which the biomarkers improved the discriminatory ability of the models beyond the discrimination provided by the clinical variables listed above. We also calculated the net reclassification improvement (NRI) for each biomarker using the category-free extension of NRI for time-to-event data. 21 Finally, we addressed the question of whether these biomarkers are helpful in selecting a particular treatment strategy (ie, whether there is a differential effect of treatment across the range of values of the biomarker). In the Hypothesis 1 cohort, we examined whether CABG+medical therapy had a greater (or lesser) effect on clinical outcomes compared with medical therapy alone depending on the value of the biomarkers. This assessment was performed by examining treatment by biomarker interactions using the Cox model, making full use of the continuous range of biomarker values and the shape of the biomarker relationships with clinical outcomes. Identical analyses were performed in the Hypothesis 2 cohort.
Because investigators often present biomarker data in the form of tertiles, we performed a secondary analysis on the basis of tertiles of each biomarker where the tertiles were calculated separately in the Hypothesis 1 and the Hypothesis 2 substudy cohorts. Within each tertile, Kaplan-Meier estimates of (1) death and (2) death or cardiovascular hospitalization were calculated to illustrate and compare the gradient of risk across tertiles for each biomarker and each treatment arm within each of the biomarker substudy cohorts. HRs, 95% CIs, and P values were generated for these analyses using the Cox model. All data analysis was performed by the STICH Coordinating Center, the Duke Clinical Research Institute, Duke University, Durham, NC. All statistical analyses were performed using SAS software, version 9.2 (SAS Institute, Inc, Cary NC).
Results
Biomarkers and STICH Hypothesis 1
Description of Biomarker Cohort
Six hundred ten of the 1212 patients enrolled in STICH Hypothesis 1 participated in the biomarker substudy. Four hundred seventy-nine patients provided a blood sample for the measurement of norepinephrine, 607 for BNP, and 607 for sTNFR-1, with 606 patients having measurements of both BNP and sTNFR-1. To provide comparative assessments of BNP and sTNFR-1 in an identical set of patients, the 606 patients with both measurements constitute the primary Hypothesis 1 biomarker substudy population. Table 1 shows selected baseline characteristics of the 606 biomarker substudy patients compared with the remainder of the STICH Hypothesis 1 patients. A full list of baseline characteristics of these 2 patient groups can be found in Table I in the online-only Data Supplement. Although there were some baseline differences between the 2 groups, there was a high degree of concordance in important baseline characteristics, including sex, the presence of diabetes mellitus, the presence of hypertension, severity of coronary disease, New York Heart Association Classification, and serum creatinine. Importantly, treatment assignment had the same effect on patient outcome in the patients enrolled in the STICH Hypothesis 1 biomarker substudy as it did in the total STICH population (the HR comparing medical therapy plus CABG versus medical therapy alone was 0.86 in the biomarker substudy patients and 0.86 in the remaining patients, identical to the treatment comparison in the overall STICH Hypothesis 1 population; Figure I in the online-only Data Supplement).
In the Hypothesis 1 cohort, the median value of BNP was 313 pg/mL (180, 569; 25th and 75th percentiles), the median sTNFR1 was 1399 pg/mL (1112, 1955; 25th and 75th percentiles), and the median norepinephrine was 507 pg/mL (337, 769; 25th and 75th percentiles).
Biomarker Relationships With Clinical Outcomes
Across the continuum of BNP, there was a sharply increasing risk of death with increasing values of BNP, up to a value of ≈400 pg/mL. Beyond that point, the level of risk exhibited no further increase ( Figure 1 ). For sTNFR-1, the risk was relatively level for low values up to ≈1200 pg/mL, beyond which the risk increased sharply with increasing values of sTNFR-1 up to a level of ≈2200 pg/mL. Beyond that point, no further increase was observed ( Figure 2 ). For the composite end point of death or cardiac hospitalization, the patterns for the 2 biomarker relationships were similar to that observed for mortality alone except that there continued to be a slight further increase in risk as BNP increased beyond 400 pg/mL.
As seen in Table 2 , plasma levels of sTNFR-1 and BNP were highly predictive of both the primary and the secondary outcome variables in Hypothesis 1 by univariate analysis. For example, both BNP (χ 2 =40.6; P<0.0001) and sTNFR-1 (χ 2 =38.9; P<0.0001) contributed important prognostic information in Hypothesis 1 patients with respect to the risk of reaching the primary end point of death. Similar results were found for the secondary end point of death or cardiovascular hospitalization. Moreover, when considered in the context of multivariable analysis with the predefined baseline clinical variables, both BNP and sTNFR-1 contributed independent prognostic information for mortality beyond the information provided by the large array of other clinical factors (the addition of BNP to the clinical factors added a χ 2 of 11.9; P<0.001 and the addition of sTNFR-1 added a χ 2 of 18.5; P<0.0001). Translating these numbers into the increased level of risk conferred by increases in BNP or sTNFR-1, even after adjusting for the other clinical variables, an increase of 100 pg/mL in BNP (up to a level of ≈400 pg/mL) increased the risk of death by 30% (adjusted HR, 1.30; 95% CI, 1.11-1.51), and an increase in sTNFR-1 of 200 pg/mL (in the range of 1200-2200) elevated the risk of death by ≈20% (adjusted HR, 1.19; 95% CI, 1.10-1.29). Similarly significant results were seen when analyzing the risk of a patient BNP indicates brain natriuretic peptide; CAD, coronary artery disease; DF, degrees of freedom; ESVI, end-systolic volume index; HF, heart failure; MI, myocardial infarction; STICH, Surgical Treatment for Ischemic Heart Failure; and TNFR, tumor necrosis factor-alpha receptor-1.
*The covariates include treatment assigned, stratum, age, sex, race, HF class at baseline, history of MI, ESVI, Duke CAD Index, creatinine, hemoglobin, mitral regurgitation, hyperlipidemia, diabetes mellitus, history of stroke, history of atrial flutter/fibrillation, and whether or not a patient can do the baseline 6-minute walk. These are variables either prospectively specified in STICH protocol or with significant prognostic effect.
reaching the secondary end point of death or cardiovascular hospitalization ( Table 2) .
Discrimination and NRI
The improvements in discrimination (c-index) produced by BNP or sTNFR-1 for either end point were small, namely 0.01 in each case. For mortality, the c-index increased from 0.67 to 0.68 for either biomarker. Such a small increase is not surprising, however, given prior experience with this measure of discrimination. 22 NRI for BNP beyond the clinical factors was a respectable 0.29 for mortality, although only 0.17 for death or cardiovascular hospitalization. For sTNFR-1, the NRI was 0.21 for mortality and 0.37 for death or cardiovascular hospitalization.
Plasma levels of norepinephrine were not associated with the risk of meeting either the primary end point of mortality (χ 2 =<0.1; P=0.819) or the secondary end-point of death or cardiovascular hospitalization (χ 2 =0.1; P=0.730).
Tertile Analysis
We assessed the relationship between tertile levels of biomarkers and outcomes in patients enrolled in Hypothesis 1 of STICH. There was a direct relationship between the rate of death and the BNP tertile for patients randomly assigned to CABG (χ 2 =21.6; P<0.001) with the highest tertile group having the worst prognosis and the lowest tertile group having the best prognosis ( Figure 3A) . Similarly, increasing BNP tertiles were associated with a higher rate of death in Hypothesis 1 patients randomized to medical therapy (χ 2 =14.8; P=0.001). Tertiles of sTNFR-1 levels were also predictive of the rate of death in Hypothesis 1 patients undergoing CABG ( Figure 3B ; χ 2 =17.3; P<0.001) and in those undergoing medical therapy (χ 2 =17.0; P<0.001). Tertiles of sTNFR-1 levels were also highly predictive of a patient reaching the secondary end point of death or cardiovascular hospitalization if they were randomly assigned to medical therapy (χ 2 =14.2; P=0.001) or to CABG (χ 2 =13.1; P=0.001). In contrast, tertiles of BNP levels were only nominally useful in predicting the occurrence of death or cardiovascular hospitalization in patients allocated to CABG (χ 2 =8.6; P=0.014) and were not significant in predicting this end point in patients randomized to medical therapy (χ 2 =4.1; P=0.129).
Consistency of Prognostic Relationships Across Treatments
There was no evidence of an interaction between treatment and any of the 3 biomarkers for either the primary mortality end point or the composite of death or hospitalization for a cardiac cause (interaction P values were all >0.2 and most were considerably larger, both unadjusted and adjusted for other clinical factors). Thus, the relative effect of CABG was consistent across the range of all the biomarker values represented in the Hypothesis 1 cohort, and the prognostic effect of the biomarkers did not vary by treatment.
Biomarkers and STICH Hypothesis 2
Description of Biomarker Cohort
Although there were a total of 1000 patients enrolled in STICH Hypothesis 2, we excluded the 76 patients who were also in Hypothesis 1 and restricted the Hypothesis 2 biomarker analysis to the completely independent cohort of 924 patients.
Six hundred eighty-two of the 924 patients participated in the biomarker substudy. Of those, 578 patients provided a blood sample for the measurement of norepinephrine, 676 for BNP, and 679 for sTNFR-1 measurements (with 676 patients having blood samples for both BNP and sTNFR-1 measurements). Again, to provide comparative assessments of BNP and sTNFR-1 in an identical set of patients, the 676 patients with both measurements constitute the primary Hypothesis 2 biomarker substudy population. For the Hypothesis 2 cohort, the median value of BNP was 274 pg/mL (178, 543; 25th and 75th percentiles), the median sTNFR1 was 1358 pg/mL (1063, 1761; 25th and 75th percentiles), and the median norepinephrine was 404 pg/mL (250, 583; 25th and 75th percentiles). Table 3 presents selected baseline characteristics of these 676 patients compared with the remainder of the 924 study patients. As observed in Hypothesis 1, there was good concordance between baseline characteristics in the 2 groups. A full list of baseline characteristics of these 2 groups can be found in Table II in the online-only Data Supplement. Furthermore, as seen in STICH Hypothesis 1, treatment assignment had the same effect on patient outcome in the patients enrolled in the Hypothesis 2 biomarker substudy as it did in the total Hypothesis 2 population. There was no difference in the primary end point of mortality or cardiovascular hospitalization when comparing patients randomized to CABG alone versus those randomized to CABG plus SVR ( Figure II in the onlineonly Data Supplement).
Biomarker Relationships With Clinical Outcomes
The relationships between each of the biomarkers (BNP, sTNFR-1) and the end points of death or cardiac hospitalization and death alone in the Hypothesis 2 cohort were remarkably similar to the relationships observed in Hypothesis 1 patients. Across the continuum of BNP, there was a sharply increasing risk of death and of death or cardiovascular hospitalization with increasing values of BNP, up to a value in this case of ≈300 pg/mL. Beyond that point, there was only a small and gradual increase in risk with increasing values of BNP (Figure 4 ). For sTNFR-1, again the risk was level up to ≈1200 pg/mL, beyond which the risk increased sharply with increasing values of sTNFR-1 up to ≈2200 pg/mL, beyond which no further increase was observed ( Figure 5) . Table 4 demonstrates that for patients allocated to STICH Hypothesis 2, both plasma levels of BNP (χ 2 =30.3) and sTNFR-1 (χ 2 =45.5) were highly predictive in univariate analysis (P<0.001) for the primary end point of death or cardiac hospitalization. Similarly, significant results were observed when analyzing the risk of a patient reaching the secondary end point of death. In multivariable analysis, the prognostic information contributed by BNP (χ 2 =6.0; P=0.049) and sTNFR-1(χ 2 =8.8; P=0.003) remained statistically significant even after accounting for the other clinical information, including highly prognostic factors, such as end-systolic volume index. Translating these numbers into the increased level of risk conferred by increases in BNP or sTNFR-1 after adjusting for the other clinical variables, an increase of 100 pg/mL in BNP (up to a level of ≈300 pg/mL) increased the risk of death or cardiovascular hospitalization by 26% (adjusted HR, 1.26; 95% CI, 1.04-1.52), and an increase in sTNFR-1 of 200 pg/mL (in the range of 1200-2200) also elevated the risk of death by 26% (adjusted HR, 1.26; 95% CI, 1.08-1.47). Consistent results were seen when analyzing the Hypothesis 2 secondary end point of death. Therefore, the predictive value of BNP and sTNFR-1 observed in the independent Hypothesis 2 cohort is very similar to the results obtained in the Hypothesis 1 cohort.
Discrimination and NRI
In the Hypothesis 2 cohort, the improvement in discrimination (c-index) produced by BNP or sTNFR-1 for either end point was very small, namely <0.01 in each case. For mortality, the c-index increased from 0.728 to 0.733 for BNP and from 0.728 to 0.731 for sTNFR-1. NRI for BNP beyond the clinical factors was 0.13 for mortality and 0.15 for death or cardiovascular hospitalization. For sTNFR-1 the NRI was higher, namely 0.38 for mortality and 0.30 for death or cardiovascular hospitalization.
Plasma levels of norepinephrine did not have a significant relationship with the primary end point of death or cardiovascular hospitalization in the Hypothesis 2 patient cohort (χ 2 =2.6; P=0.457). There was a significant univariate association of norepinephrine with the secondary end point of mortality (χ 2 =8.3; P=0.004), which was not significant after adjusting for the clinical variables (χ 2 =1.3; P=0.258).
Tertile Analysis
As observed in STICH Hypothesis 1, grouping of patients in tertiles based on their levels of BNP or sTNFR-1 demonstrated a marked gradient of risk among patients enrolled in Hypothesis 2 and randomly assigned to either CABG alone or CABG plus left ventricular reconstruction when assessing the primary end point of death or cardiovascular hospitalization ( Figure 6A and 6B ). There was a direct relationship between the rate of death or cardiovascular hospitalization and the BNP tertile for Hypothesis 2 patients randomly assigned to CABG (χ 2 =8.3; P=0.016) with the lowest tertile group having the best prognosis ( Figure 6A) . Similarly, increasing BNP tertiles were associated with a higher rate of death or cardiovascular hospitalization in Hypothesis 2 patients randomized to CABG plus SVR (χ 2 =20.7; P<0.001). Tertiles of sTNFR-1 levels were also predictive of the rate of death or cardiovascular hospitalization in Hypothesis 2 patients undergoing CABG ( Figure 6B ; χ 2 =20.5; P<0.001) and in those undergoing the combination of CABG plus SVR (χ 2 =23.7; P<0.001). Tertiles of sTNFR-1 levels were also highly predictive of a patient reaching the secondary end point of death if they were randomly assigned to CABG (χ 2 =17.5; P<0.001) or to CABG plus SVR (χ 2 =31.4; P<0.001). In contrast, tertiles of BNP levels were only marginally associated with the secondary end point of death in patients allocated to CABG (χ 2 =4.1; P=0.128) and strongly associated with death in patients allocated to CABG plus SVR (χ 2 =31.8; P<0.001).
Consistency of Prognostic Relationships Across Treatments
Similar to the Hypothesis 1 cohort, there was no evidence of an interaction between treatment and any of the 3 biomarkers for either end point (large interaction P values). Thus, the absence of a treatment effect of CABG+surgical ventricular reconstruction was consistent across the range of biomarker values represented in the Hypothesis 2 cohort, and the predictive ability of the biomarkers did not vary by treatment arm.
Discussion
Investigators have developed a group of risk indexes that are predictive of postoperative mortality, morbidity, and hospital stay in patients undergoing CABG. [2] [3] [4] [5] [6] These risk indexes have used a variety of clinical and laboratory evaluations but have questionable predictive value, limited accuracy, and are of uncertain value as a clinical tool. 7 We report results from 2 independent but closely related clinical trials demonstrating that sTNFR-1 and BNP, but not norepinephrine, are strongly associated with outcome in patients with ischemic heart failure undergoing CABG or the combination of CABG and left ventricular reconstruction when assessed both by univariate and by multivariable analyses. BNP and sTNFR-1 levels were also predictive of outcomes in patients receiving optimal medical therapy. However, the highly prognostic value of these 2 biomarkers was independent of treatment. Importantly, the addition of biomarkers to a group of historical, morphological, hemodynamic, and functional parameters significantly improved the predictive value of this group of clinical variables. Interestingly, sTNFR-1 seemed in these analyses to generally be more strongly associated with outcome, either alone or in combination with clinical covariables, than was BNP.
Our finding that norepinephrine was not a useful predictor of outcome in patients with heart failure is in contrast to previous studies. 8, [23] [24] [25] This disparity could be explained by several factors. Earlier studies were all in patients with relatively advanced heart failure, a substantial number of whom would not have been eligible for the STICH protocol. Accurate assessment of plasma norepinephrine levels requires that patients be free of external stimuli that would enhance adrenergic drive at the time of sample collection. Many of the samples for STICH were drawn contemporaneously with a hospitalization for CABG, a time when patients might be expected to have a high level of adrenergic drive. Finally, we assessed norepinephrine levels in a group of patients with ischemic heart failure, whereas earlier studies evaluated norepinephrine levels in patients with both ischemic and nonischemic disease, another possible confounding factor.
Our finding that elevated plasma levels of BNP were associated with a worse outcome in a heart failure population undergoing consideration for CABG is consistent with earlier studies in patients with both ischemic and nonischemic heart failure. Measurement of the levels of BNP and NT-pro-BNP is useful in the diagnosis of heart failure and risk stratification in the emergency department, at the time of hospital admission, and at the time of hospital discharge when used as a complement to the clinical examination and other available diagnostic tests, including renal function and body mass index. 9, 26 More recently, Hutfless et al 27 reported that high preoperative BNP levels predicted postoperative complications and 1-year mortality after CABG, although they reported that BNP levels were best used in conjunction with multivariable risk indexes. BNP has also been shown in a group of observational cohort studies to be a marker of cardiac dysfunction and both short and long-term survival in patients undergoing CABG. 28 Plasma levels of sTNFR-1 were strongly associated with clinical outcome in patients with heart failure, while exceeding the predictive value of levels of BNP in Hypothesis 2 and proving slightly stronger than the predictive value of BNP in Hypothesis 1. These findings were both unanticipated and novel. The circulating levels of the proinflammatory cytokines, TNFα, interleukin (IL)-1b, and IL-6, and the soluble fragments of their cognate receptors, sTNF-R1, STNF-R2, IL-2sR, and IL-6sR, are elevated in patients with heart failure and are thought to play a role in the development of progressive left ventricular dysfunction and remodeling. [29] [30] [31] [32] [33] The soluble portion of the type 1 (sTNFR-1, p55, TNFSF1A) and type 2 (TNFR2, p75, TNFSF1B) TNFα receptors is shed into the circulation in response to a variety of stimuli, including TNFα. These soluble receptors are thought to bind to TNF and block the activity of this cytokine when it is released into the circulation. 34 Thus far, the role of sTNFR-1 in predicting Event-rate curves are presented on the left for patients randomized to coronary artery bypass grafting (CABG) and on the right for patients randomized to the combination of CABG and left ventricular reconstruction. SVR indicates surgical left-ventricular reconstruction. CI indicates confidence interval. outcome in patients with heart failure has received far less attention than the role of BNP. Although both cytokines and cytokine receptors have been found to be independently predictive of mortality in patients with advanced heart failure, 10, 16, 35 their relationship to outcomes in patients with ischemic disease undergoing surgical revascularization or medical therapy has not been defined. It is unclear why sTNFR-1 was more strongly predictive of risk than BNP in this group of patients with heart failure and coronary artery disease; however, it might relate, at least in part, to the greater stability of sTNFR-1 in the plasma 36 and the fact that unlike BNP, it is not influenced by sex and age.
We analyzed the biomarkers as continuous variables because it did not require grouping patients arbitrarily or choosing arbitrary cut points and as illustrated by the data, the risk varies over a continuous range. The lowest values for each biomarker were at the lowest risk, and the highest values were at the highest risk, but the risk did not increase linearly over the entire range of the biomarkers. Different clinicians have different threshold levels of risk, and therefore providing the data in this format allows physicians to decide what cutoff levels for risk stratification might be most appropriate for their practice and for individual patients. The measurement of these biomarkers must also be viewed in the context of each patient. For example, a patient with a BNP of >1000 pg/mL certainly has a surgical risk that is quite significant; however, a patient who is severely limited by their angina might be willing to undergo CABG to improve their quality of life, recognizing the significant operative risk.
In summary, heart failure secondary to coronary artery disease continues to be associated with significant morbidity and mortality. Analysis of the biomarker substudy of the STICH trial, which incorporated patients in Hypothesis 1 and Hypothesis 2, shows that elevated levels of 2 biomarkers, sTNFR-1 and BNP, were strongly associated with outcomes in 2 large and independent studies of patients who received either medical therapy or surgical revascularization, thus providing important cross-validation for the prognostic importance of these 2 biomarkers. It bears emphasis that elevated levels of sTNFR-1 and BNP also enhanced the predictive abilities of a well-established set of time-honored clinical and hemodynamic variables. The finding that the predictive value of levels of both BNP and sTNFR-1 did not increase linearly across the full range of biomarker values raises questions about the importance of modest changes in biomarker levels in those with very high levels at baseline and the rationale for performing serial biomarker levels in these patients. Because there were no differential treatment effects across the range of these biomarkers in either the Hypothesis 1 or the Hypothesis 2 cohort, the prognostic value of these biomarkers is applicable and consistent for each of the different treatment options. Taken together, the results of this study provide a strong rationale for using validated biomarkers to assess prognosis in this challenging group of patients.
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